<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y90449e8vk.txt
<DESCRIPTION>PHIBRO ANIMAL HEALTH CORPORATION
<TEXT>
<PAGE>

================================================================================

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                       ----------------------------------

                                    FORM 8-K

                       ----------------------------------


                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934



        Date of Report (Date of earliest event reported) October 2, 2003






                        PHIBRO ANIMAL HEALTH CORPORATION
             (Exact name of registrant as specified in its charter)


          New York                    333-64641             13-1840497
-----------------------------     ------------------   ----------------------
(State or other jurisdiction       (Commission File       (IRS Employer
     of incorporation)                 Number)       Identification Number)


                                One Parker Plaza
                           Fort Lee, New Jersey 07024
-------------------------------------------------------------------------------

              (Address of principal executive offices) (Zip Code)

                                 (201) 944-6020
-------------------------------------------------------------------------------

              (Registrant's telephone number, including area code)


================================================================================


<PAGE>

Item 5. Other Events and Regulation FD Disclosure.

     Phibro Animal Health Corporation (the "Company"), formerly Philipp Brothers
Chemicals, Inc., which previously issued a press release announcing a consent
solicitation with respect to its 9 7/8% Senior Subordinated Notes Due 2008 (the
"Existing Notes"), issued a press release on October 2, 2003 announcing that it
had received and accepted the requisite consents from the holders of a majority
of the Existing Notes, and that the proposed amendments to the indenture
governing the Existing Notes set forth in the Company's Consent Solicitation
Statement dated September 24, 2003 have become effective.


     A copy of the press release is attached as Exhibit 99.1 to this Report, and
a copy of the supplemental indenture to the indenture governing the Existing
Notes, effecting the amendments described in the Consent Solicitation Statement
is attached as Exhibit 99.2 to this Report.


     Nothing in this Report shall  constitute an offer to purchase or sell, or a
solicitation of an offer to purchase or sell, any securities of the Company.


     This Report includes statements that constitute forward-looking statements
within the meaning of Section 27A of the Securities Act and Section 21E of the
Exchange Act. These statements are subject to risks and uncertainties.
Forward-looking statements include information concerning possible or assumed
future results of operations of the Company and its affiliates. These statements
may relate to, but are not limited to, information and assumptions about capital
and other expenditures, dividends, financing plans, capital structure, cash
flow, pending legal and regulatory proceedings and claims, including
environmental matters, future economic performance, operating income, cost
savings, management's plans, goals and objectives for future operations and
growth. These forward-looking statements generally are accompanied by words such
as "intend," "anticipate," "believe," "estimate," "expect," "should" or similar
expressions. It should be understood that these forward-looking statements are
necessarily estimates reflecting the best judgment of the Company's senior
management, not guarantees of future performance. They are subject to a number
of assumptions, risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in the forward-looking
statements. Important assumptions relating to the forward-looking statements
include, among others, assumptions regarding demand for the Company's products,
the expansion of product offerings geographically or through new applications,
the timing and cost of planned capital expenditures, competitive conditions and
general economic conditions. These assumptions could prove inaccurate.
Forward-looking statements also involve risks and uncertainties, which could
cause actual results that differ materially from those contained in any
forward-looking statement. Many of these factors are beyond the Company's
ability to control or predict. Such factors include, but are not limited to, the
following: the Company's substantial leverage and potential inability to service
its debt; the Company's dependence on distributions from its subsidiaries; risks
associated with the Company's international operations and significant foreign
assets; the Company's dependence on its Israeli operations; competition in each
of the Company's markets; potential environmental liability; potential
legislation affecting the use of medicated feed additives; extensive regulation
by numerous government authorities in the United States and other countries; the
Company's reliance on the continued operation and sufficiency of its
manufacturing facilities; the Company's reliance upon unpatented trade secrets;
the risks of legal proceedings and general litigation expenses; potential
operating hazards and uninsured risks; the risk of work stoppages; the Company's
dependence on key personnel; and other factors discussed in the Company's
filings with the U.S. Securities and Exchange Commission.


     Undue reliance should not be placed on forward-looking statements, which
speak only as of the date of this Report.


     All subsequent written and oral forward-looking statements attributable to
the Company or any person acting on its behalf are expressly qualified in their
entirety by the cautionary statements contained or referred to


                                       2

<PAGE>

in this Report and any other cautionary statements that may accompany such
forward-looking statements. The Company does not undertake any obligation to
release publicly any revisions to these forward-looking statements to reflect
events or circumstances after the date of this document or to reflect the
occurrence of unanticipated events, unless the securities laws require the
Company to do so.


Item 7. Financial Statements and Exhibits




      (c) Exhibits



            99.1 Press Release, dated October 2, 2003
            99.2 Fourth Supplemental Indenture














                                       3
<PAGE>

                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                      PHIBRO ANIMAL HEALTH CORPORATION


Dated: October 2, 2003                By: /s/ Jack C. Bendheim
                                          --------------------------------------
                                          Jack C. Bendheim,
                                          Chairman of the Board and President


                                      By: /s/ Gerald K. Carlson
                                          --------------------------------------
                                          Gerald K. Carlson,
                                          Chief Executive Officer


                                      By: /s/ Richard G. Johnson
                                          -------------------------------
                                          Richard G. Johnson,
                                          Chief Financial Officer


                                       4


<PAGE>



                                 Exhibit Index

Exhibit No.         Description

99.1                Press Release, dated October 2, 2003
99.2                Fourth Supplemental Indenture




                                       5


</TEXT>
</DOCUMENT>
